Joan edukira
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Aurreratua
  • Anti-angiogenic effect of tamo...
  • Erreferentzia bihurtu
  • SMS
  • Bidali
  • Imprimir
  • Erregistroa esportatu
    • Nora RefWorks
    • Nora EndNoteWeb
    • Nora EndNote
  • Permanent link
Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients

Show other versions (1)
Xehetasun bibliografikoak
Egile Nagusiak: Mele, T, Generali, D, Fox, S, Brizzi, M, Bersiga, A, Milani, M, Allevi, G, Bonardi, S, Aguggini, S, Volante, M, Dogliotti, L, Bottini, A, Harris, A, Berruti, A
Formatua: Journal article
Argitaratua: 2010
  • Aleari buruzko argibideak
  • Deskribapena
  • Other Versions (1)
  • Antzeko izenburuak
  • MARC erregistroa

Antzeko izenburuak

  • Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
    nork: Mele, T, et al.
    Argitaratua: (2010)
  • The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
    nork: Fox, S, et al.
    Argitaratua: (2011)
  • The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
    nork: Fox, S, et al.
    Argitaratua: (2011)
  • Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
    nork: Generali, D, et al.
    Argitaratua: (2009)
  • Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
    nork: Generali, D, et al.
    Argitaratua: (2009)

Bilaketa aukerak

  • Bilaketaren historia
  • Bilaketa aurreratua

Gehiago bilatu

  • Katalogoa arakatu
  • Bilaketa alfabetikoki
  • Esploratu kanalak
  • Erreserba egin ezazu
  • Berriak liburutegietan

Laguntza behar al duzu?

  • Bilaketa egiteko aholkuak
  • Galdetu liburuzainari
  • FAQ